Kliničke studije za KOPB u državi Colorado
15 studija za KOPB traži sudionike na lokacijama u državi Colorado.
Gradovi u državi Colorado
Službeni tekst studije (engleski)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Aurora
- Research Site, Denver
U tijeku regrutacijaFaza 3
Od 40 do 80 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005, Boulder
- Critical Care Pulmonary & Sleep Associates- Site Number : 8400081, Lakewood
U tijeku regrutacijaFaza 3
Od 40 do 80 godina · Oba spola · Ažurirano 1. lis 2026. · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Lynn Institute of Denver, Aurora
U tijeku regrutacijaFaza 2
Od 40 do 85 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07684820A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- National Jewish Health Medical Center, Denver
U tijeku regrutacijaFaza 2
Od 40 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07759245An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- UCHealth - Medical Center of the Rockies, Loveland
U tijeku regrutacija
Od 40 do 80 godina · Oba spola · Ažurirano 17. ruj 2026. · NCT06035120Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- National Jewish Health, Denver
U tijeku regrutacijaFaza 2
Od 40 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07059091eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lakewood
U tijeku regrutacijaFaza 3
Od 40 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07177339MoblO2 to Maintain Oxygenation
- National Jewish Health, Denver
U tijeku regrutacija
Od 25 do 95 godina · Oba spola · Ažurirano 22. srp 2026. · NCT07704567SPIROMICS Study of Early COPD Progression (SOURCE)
- National Jewish Health, Denver
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 30 do 55 godina · Oba spola · Ažurirano 3. lip 2026. · NCT05033990Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
U tijeku regrutacijaFaza 2
Od 35 do 89 godina · Oba spola · Ažurirano 15. svi 2026. · NCT05937854Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
U tijeku regrutacija
Od 40 godina i više · Oba spola · Ažurirano 8. svi 2026. · NCT05896579Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease
- University of Colorado Anschutz Medical Campus, Aurora
U tijeku regrutacija
Od 40 godina i više · Oba spola · Ažurirano 8. svi 2026. · NCT07576894Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Aurora
U tijeku regrutacijaFaza 3
Od 40 do 80 godina · Oba spola · Ažurirano 9. tra 2026. · NCT06961214PiMZ Longitudinal Cohort (PiMZ Logic)
- National Jewish Health, Denver
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 16. sij 2026. · NCT06505603PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
- University of Colorado, Denver
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 12. lis 2023. · NCT05306743Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.